MX342511B - Metodos y composiciones para tratar la enfermedad de raynaud. - Google Patents

Metodos y composiciones para tratar la enfermedad de raynaud.

Info

Publication number
MX342511B
MX342511B MX2013011662A MX2013011662A MX342511B MX 342511 B MX342511 B MX 342511B MX 2013011662 A MX2013011662 A MX 2013011662A MX 2013011662 A MX2013011662 A MX 2013011662A MX 342511 B MX342511 B MX 342511B
Authority
MX
Mexico
Prior art keywords
raynaud
disease
compositions
methods
phenomenon
Prior art date
Application number
MX2013011662A
Other languages
English (en)
Other versions
MX2013011662A (es
Inventor
Richard Martin
Daniel W Frank
Bassam B Damaj
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of MX2013011662A publication Critical patent/MX2013011662A/es
Publication of MX342511B publication Critical patent/MX342511B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

En varias modalidades, se proporcionan métodos y composiciones para tratar la enfermedad de Raynaud y el fenómeno de Raynaud. La administración tópica de una composición semisólida que comprende un compuesto de prostaglandina E1 proporciona el alivio deseado de la enfermedad de Raynaud o el fenómeno de Raynaud sin las posibles complicaciones de la administración sistémica. La composición semisólida se puede administrar según sea necesario, o en un régimen de varias dosis por día.
MX2013011662A 2011-04-07 2012-04-06 Metodos y composiciones para tratar la enfermedad de raynaud. MX342511B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472988P 2011-04-07 2011-04-07
PCT/US2012/032577 WO2012139033A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating raynaud's disease

Publications (2)

Publication Number Publication Date
MX2013011662A MX2013011662A (es) 2013-12-12
MX342511B true MX342511B (es) 2016-10-03

Family

ID=46969575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011662A MX342511B (es) 2011-04-07 2012-04-06 Metodos y composiciones para tratar la enfermedad de raynaud.

Country Status (8)

Country Link
US (4) US8940794B2 (es)
EP (1) EP2693877A4 (es)
JP (1) JP2014510156A (es)
BR (1) BR112013025744A2 (es)
CA (1) CA2838109C (es)
MX (1) MX342511B (es)
RU (1) RU2633236C2 (es)
WO (1) WO2012139033A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
CN109288848A (zh) * 2018-11-27 2019-02-01 西安力邦肇新生物科技有限公司 前列腺素e1甲酯在制备扩张血管药物中的应用
WO2022032141A1 (en) * 2020-08-07 2022-02-10 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029814A (en) 1975-12-29 1977-06-14 The Upjohn Company Phenyl-substituted prostaglandin-e type analogs
US4212987A (en) 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
DE3704825A1 (de) 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
EP0503887B1 (en) 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
DE69327432T2 (de) 1992-02-07 2000-05-18 Kaken Pharma Co Ltd Heilmittel für wunden und hämorrhoiden
DE69434199T2 (de) 1993-10-07 2005-12-29 Odontex, Inc., Lawrence Absorptionsförderer für topische pharmazeutische formulierungen
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US20020165122A1 (en) 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
TW473834B (en) 1998-05-01 2002-01-21 Ibm Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
CA2442479C (en) 1999-05-13 2005-12-13 Nexmed Holdings, Inc. Topical compositions for prostaglandin e1 delivery
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105572B2 (en) 2000-02-04 2006-09-12 Takeda Pharmaceutical Company Limited Stable emulsion compositions
US20060148907A1 (en) 2002-07-24 2006-07-06 Nicholson David M Topical antinflammatory preparations of y-terpinene
KR20050084890A (ko) * 2002-10-30 2005-08-29 머크 프로스트 캐나다 앤드 캄파니 피리도피롤리진 및 피리도인돌리진 유도체
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
PL2084124T3 (pl) * 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
EP2011496A1 (en) 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
US8940794B2 (en) * 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease

Also Published As

Publication number Publication date
US9517218B2 (en) 2016-12-13
US20180333377A1 (en) 2018-11-22
US8940794B2 (en) 2015-01-27
BR112013025744A2 (pt) 2016-08-16
US20160081954A1 (en) 2016-03-24
US9855231B2 (en) 2018-01-02
RU2633236C2 (ru) 2017-10-11
JP2014510156A (ja) 2014-04-24
US10632086B2 (en) 2020-04-28
EP2693877A4 (en) 2014-11-19
CA2838109C (en) 2020-06-09
US20140200274A1 (en) 2014-07-17
RU2013141836A (ru) 2015-05-20
MX2013011662A (es) 2013-12-12
EP2693877A1 (en) 2014-02-12
US20160331761A1 (en) 2016-11-17
CA2838109A1 (en) 2012-10-11
WO2012139033A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ631144A (en) Compositions and methods for transmucosal absorption
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
NZ706108A (en) Topical ketoprofen composition
MX2013011662A (es) Metodos y composiciones para tratar la enfermedad de raynaud.
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
BR112013025878A2 (pt) composição farmacêutica e método para produzir uma composição farmacêutica
WO2015033302A3 (en) Fulvestrant compositions
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
WO2015003021A3 (en) Dietary supplements and composition for treating cancer
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX362917B (es) Metodos para hacer seguros complejos de coordinacion micelares para el tratamiento de plantas y formulaciones para los mismos.
WO2009089366A3 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
WO2014015137A3 (en) Compositions and methods for treating dysproliferative diseases
MX2015011588A (es) Tratamiento de combinacion.
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.

Legal Events

Date Code Title Description
FG Grant or registration